INTRODUCTION
conditions of severe and moderate thrombocytopeniaP 16 P . In this study we want to show that IPM has potential clinical use in the treatment of bleeding due to thrombocytopenia.
MATERIALS AND METHODS

Preparation of IPM
IPM is prepared from 8 outdated platelet units of Tehran Blood Transfusion Center. The units were pooled and centrifuged for 15 min at 1000 RPM to remove contaminating red cells and white cells. The supernatant was centrifuged for 30 min at 2500 RPM to remove plasma. The precipitate was resuspended in 25 ml physiological saline solution (0.9 g%). For lysis and disruption of platelets, freeze-thaw procedure was repeated three times at -80°C and room temperature for 6 and 2 h respectively. The solution was washed twice with physiological saline solution for removing of intracellular components by centrifugation (30 min at 2500 RPM). The precipitate was resuspended in 45 ml of the same solution.
Pasteurization of sample
The sample of IPM with 0.4 M sodium caprylate concentration was prepared and heated at 60°C for 20 h to inactivate possible viral or bacterial contaminants and formulated with sucrose 1 M and human serum albumin 0.1% P
17
P .
In vivo haemostasis assay
The hemostatic activity of IPM was measured by bleeding time assay to correct prolonged bleeding time in thrombocytopenic rabbits. White New Zealand rabbits 3 to 3.3 Kg in weight were made thrombocytopenic by subcutaneous administration of busulfan dissolved in polyethylene glycol 400 (15 mg/kg on Days 0 ,2, 4 and 6). We measured platelet count and bleeding time on Day Platelet transfusion is an effective therapy to control bleeding in thrombocytopenic patients. Unfortunately, blood platelet units are generally stored in blood banks for 3-5 days, thereafter they are discardedP 1-2 P . For preserving platelets for a long period, a number of attempts have been taken to develop substitutes for platelets, as possible alternatives to currently available platelet concentrates. A number of studies have shown that platelet preparations with impaired metabolic or functional integrity still retain a certain degree of hemostatic propertyP [3] [4] [5] [6] P . Infusible platelet membrane (IPM) prepared from outdated human platelets have been developed as an alternative to standard platelet concentrates, with the additional advantage of long shelf life and increased viral safety and have confirmed useful in shortening bleeding time in rabbits with experimentally induced thrombocytopeniaP 7 P . Platelet microparticles are microvesicles of platelet membranes that form during the activation or mechanical disruption of plateletsP 8 P . They form spontaneously during platelet storage and can be detected in platelet concentratesP [9] [10] [11] P , fresh frozen plasma and cryoprecipitateP 12 P . They have properties of procoagulant activityP 13 P . Due to these microparticles have similar hemostatic properties as intact platelets, they can be considered as a strategy for the development of a platelet substitute. However, the earliest efforts of these preparations were not successful in vivo and produced considerable distress in experimental animalsP 
RESULTS AND DISCUSSION
In previous investigations bleeding time has been used to assessment of the hemostatic effectiveness of various agents in the rabbit modelP [18] [19] [20] P . In this study, we administered IPM at a dose of 2 mg per kg, to thrombocytopenic rabbits with platelet count of 50 to 70 ×10P 3 P per μL, and we performed 48 sets of bleeding time measurements before of biosulfan injection, before and 2, 4, 6 and 24R Rhours after IPM injection. The values of bleedingtime in these 48 data sets are summarized in Table  1 . 7,9,11. Animals with 50-70 × 10P 3 P per μL with prolonged bleeding time (≥7 min) were used in this assay.
For bleeding time assay, a standard device (ITC Surgicut Bleeding time, Fisher Scientific Inc.) was used to provide uniform standardized incision depth in the ear (Incision D×L: 1.0 x 5.0 mm) with improved test standardization and reproducibility of bleeding time test results. We applied a Whattman filter paper to the flow of blood from the wound. A stopwatch was started immediately and every 30 seconds filter paper was used to draw off the blood. The time from when the incision was made until all bleeding has stopped was called the bleeding time. We determined the preinjection bleeding time in one ear and administrated IPM at a dose of 2 mg per kg by injection into the marginal vein of the other ear at a rate of 2 mL per chloride) to another group of rabbits, are summarized in Fig-1 . For comparison of results, we expressed decrease in the percentage of bleeding time elevation after the administration of IPM to thrombocytopenic rabbits (Fig-1) .
As one can see from top curve in Fig-1 , there is no significant change in the bleeding times of animals given excipient used in IPM formulation. Reduction in the percentage of bleeding time elevation during 2, 4, 6 and 24 hours after injection in the test group of rabbits were found 24.8, 39.0, 52.4 and 95.6 respectively (Fig-1) .
Because all the platelet counts in these animals are much lower than the normal mean value of 430 × 10P 3 P per μL, the bleeding times were considerably longer than the normal value of 1.7 minutes. In this study for reliability of the results, the bleeding time was measured in duplicate and the mean was calculated.
The 10 sets of percentages of bleeding time elevations, and the corresponding data from 2 administrations of excipient (sucrose and human serum albumin in 0.9% siodium Hours after IPM injection However, in this research, the bleeding time is used to determine the response in a group of rabbits, almost identical in age and weight, that are relatively healthy, though thrombocytopenic. The main point of this study is the change in the bleeding time during the early hours after the injection of IPM. An acceptable number of animals has been used, and the each assay was performed in duplicate.
Our results indicate hemostatic effectiveness of IPM in this experimental setting.
For possible usage of IPM as a drug in human and evaluation of its clinically significant consequences, human clinical trials should be performed in the future.
CONCLUSION
Reduction in the bleeding time seen in experimental animals may support clinical potential utility of IPM as a substitute for platelets in the treatment of thrombocytopenia in humans.
The results of previous study was nearly similar to our study and has shown that administration of IPM (2 mg /kg) can shorten the prolonged bleeding time in thrombocytopenic rabbits at least 4 h after infusionP 7 P ; however, in our study the maximum decrease in the percentage of bleeding time was observed at 2 h after infusion instead of 4 h. In both studies this hemostatic effect was no longer detectable after 24 h of IPM administrations.
The reduction of bleeding time in experimental animals in our study confirms the potential utility of IPM as a substitute for platelets in the treatment of thrombocytopenia in humans. The clinical utility of the bleeding time in clinical aspects is controversial. Many experts regard the bleeding time as useless, in that it does not predict surgical bleeding. Articles supporting this view are often presented by pathologists. Despite such articles, the bleeding time continues to be used by many clinicians, primarily surgeonsP [21] [22] [23] [24] [25] P .
